Candel Therapeutics, Inc.
NASDAQ:CADL
4.83 (USD) • At close November 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 0 | 0.125 | 0.125 | 0.125 | 0.125 |
| Cost of Revenue
| 23.98 | 0.987 | 0.232 | 0 | 6.607 |
| Gross Profit
| -23.98 | -0.862 | -0.107 | 0.125 | -6.482 |
| Gross Profit Ratio
| 0 | -6.896 | -0.856 | 1 | -51.856 |
| Reseach & Development Expenses
| 24.506 | 20.787 | 15.178 | 8.754 | 6.607 |
| General & Administrative Expenses
| 13.724 | 14.06 | 10.673 | 5.181 | 2.555 |
| Selling & Marketing Expenses
| 0.687 | 0 | 0 | 0 | 0 |
| SG&A
| 14.411 | 14.06 | 10.673 | 5.181 | 2.555 |
| Other Expenses
| -24.506 | -0.048 | -1.076 | -0.624 | -0.571 |
| Operating Expenses
| 14.411 | 34.799 | 24.775 | 13.311 | 8.591 |
| Operating Income
| -38.391 | -34.722 | -25.726 | -13.81 | -9.037 |
| Operating Income Ratio
| 0 | -277.776 | -205.808 | -110.48 | -72.296 |
| Total Other Income Expenses Net
| 0.452 | 15.928 | -10.398 | -3.87 | 0.797 |
| Income Before Tax
| -37.939 | -18.794 | -36.124 | -17.68 | -8.24 |
| Income Before Tax Ratio
| 0 | -150.352 | -288.992 | -141.44 | -65.92 |
| Income Tax Expense
| 0 | -15.928 | 0.053 | 4.494 | -0.226 |
| Net Income
| -37.939 | -2.866 | -36.177 | -22.174 | -8.014 |
| Net Income Ratio
| 0 | -22.928 | -289.416 | -177.392 | -64.112 |
| EPS
| -1.31 | -0.099 | -1.26 | -0.76 | -0.27 |
| EPS Diluted
| -1.31 | -0.099 | -1.26 | -0.76 | -0.27 |
| EBITDA
| -37.431 | -51.044 | -24.418 | -8.49 | -7.579 |
| EBITDA Ratio
| 0 | -408.352 | -195.344 | -67.92 | -60.632 |